ReviewClinical cancer research : an official journal of the American Association for Cancer Research2026
Predictive Biomarkers of Antibody-Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antibody-Drug Conjugates in Solid Tumor Oncology and the Frontier of Precision Immunosuppression: A Mechanistic, Translational, and Clinical Review.International journal of molecular sciences · 2026Review
- Mechanisms of resistance to antibody-drug conjugates in bladder cancer.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Antibody-drug conjugate (ADC) development is progressing rapidly, with significant impacts on the treatment landscape of clinical oncology. However, the development of predictive biomarkers to guide ADC selection has not kept pace and to date has been mostly limited to immunohistochemistry, hampering patient selection and personalized treatment recommendations. Here, we review the current state of ADC target protein assessment and the association between target expression levels and therapeutic efficacy. We discuss the limitations and challenges of existing protein assessment technology and highlight the potential clinical role of quantitative mass spectrometry-based proteomics for rapid, comprehensive, and accurate protein quantification. We propose that integrating multiplexed proteomic assays early in ADC development and clinical trial design can improve therapeutic targeting, enhance clinical trial design, and ultimately lead to more personalized ADC-based treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.